Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Next Previous
Search
Trial Profile

A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABT 767 (Primary)
  • Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Abbott Laboratories; AbbVie

    • Most Recent Events

    • 24 Jan 2019 Results evaluating relationship between HRD score, BRCA1 and BRCA2 mutation status, expression of repair proteins and response of ovarian cancers treated with ABT-767 were published in the Gynecologic Oncology.
    • 08 Jan 2018 Results assessing tolerability, pharmacokinetics and pharmacodynamics of ABT 767 in patients with BRCA1- or BRCA2-positive advanced solid tumours or high-grade serous ovarian, fallopian tube or primary peritoneal cancer, were published in the Investigational New Drugs.
    • 28 Dec 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top